VCEL Vericel Corporation

+0.16  (+1%)
Previous Close 16.63
Open 16.63
Price To Book 7.21
Market Cap 735518825
Shares 43,806,958
Volume 148,699
Short Ratio
Av. Daily Volume 682,462

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b topline data released March 2016. Full data released April 2016
Stem cells - Dilated Cardiomyopathy
FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017.
Focal chondral cartilage defects in the knee.

Latest News

  1. Vericel to Present at Needham Healthcare Conference
  2. Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
  3. Our Take On Vericel Corporation’s (NASDAQ:VCEL) CEO Salary
  4. What Makes Vericel (VCEL) a New Buy Stock
  5. Vericel to Present at Multiple Upcoming Investor Conferences
  6. Edited Transcript of VCEL earnings conference call or presentation 26-Feb-19 1:30pm GMT
  7. US Markets Lower on Tuesday
  8. Vericel Corp (VCEL) Q4 2018 Earnings Conference Call Transcript
  9. Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up
  10. Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
  11. What's in Store for Vericel (VCEL) This Earnings Season?
  12. Vericel to Participate in Multiple Upcoming Investor Conferences
  13. Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
  14. Vericel to Present at the 21st Annual Needham Growth Conference
  15. Bull or Bear: Your Investment Strategy for 2019
  16. Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
  17. featured highlights include: Alteryx, Vericel, Mitek and Materialise
  18. 4 Stocks With Recent Price Strength to Maximize Your Gains
  19. Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
  20. 5 Nasdaq Composite Stocks That Braved the Index's Bloodbath